DE69825308T2 - Verwendung von ketoliden zur vorbeugung von mit atherosklerose zusammenhängender thrombotischer komplikationen - Google Patents
Verwendung von ketoliden zur vorbeugung von mit atherosklerose zusammenhängender thrombotischer komplikationen Download PDFInfo
- Publication number
- DE69825308T2 DE69825308T2 DE69825308T DE69825308T DE69825308T2 DE 69825308 T2 DE69825308 T2 DE 69825308T2 DE 69825308 T DE69825308 T DE 69825308T DE 69825308 T DE69825308 T DE 69825308T DE 69825308 T2 DE69825308 T2 DE 69825308T2
- Authority
- DE
- Germany
- Prior art keywords
- methyl
- dideoxy
- ketolide
- use according
- pyridinyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000003835 ketolide antibiotic agent Substances 0.000 title claims description 18
- 201000001320 Atherosclerosis Diseases 0.000 title claims description 7
- 230000001732 thrombotic effect Effects 0.000 title claims description 5
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 claims description 16
- -1 oxycarbonyl - ((4- (3- (3-pyridinyl) -1H-1,2,4-triazol-1-yl) butyl) imino) Chemical class 0.000 claims description 13
- 229960003276 erythromycin Drugs 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 125000005843 halogen group Chemical group 0.000 claims description 4
- 238000011321 prophylaxis Methods 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 3
- 125000003107 substituted aryl group Chemical group 0.000 claims description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 2
- KPCZJLGGXRGYIE-UHFFFAOYSA-N [C]1=CC=CN=C1 Chemical group [C]1=CC=CN=C1 KPCZJLGGXRGYIE-UHFFFAOYSA-N 0.000 claims description 2
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims description 2
- 229910052739 hydrogen Inorganic materials 0.000 claims description 2
- 239000001257 hydrogen Substances 0.000 claims description 2
- 125000001841 imino group Chemical group [H]N=* 0.000 claims description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
- 125000005740 oxycarbonyl group Chemical group [*:1]OC([*:2])=O 0.000 claims description 2
- 238000004220 aggregation Methods 0.000 description 9
- 230000002776 aggregation Effects 0.000 description 9
- 210000004623 platelet-rich plasma Anatomy 0.000 description 9
- 150000001875 compounds Chemical class 0.000 description 8
- 239000000047 product Substances 0.000 description 7
- 150000003254 radicals Chemical group 0.000 description 6
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 5
- 230000005540 biological transmission Effects 0.000 description 4
- 230000003287 optical effect Effects 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 150000005840 aryl radicals Chemical class 0.000 description 3
- 210000001772 blood platelet Anatomy 0.000 description 3
- 125000004432 carbon atom Chemical group C* 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- XTWYTFMLZFPYCI-KQYNXXCUSA-N 5'-adenylphosphoric acid Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XTWYTFMLZFPYCI-KQYNXXCUSA-N 0.000 description 2
- XTWYTFMLZFPYCI-UHFFFAOYSA-N Adenosine diphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(O)=O)C(O)C1O XTWYTFMLZFPYCI-UHFFFAOYSA-N 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 125000000623 heterocyclic group Chemical group 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- LDMOEFOXLIZJOW-UHFFFAOYSA-N 1-dodecanesulfonic acid Chemical compound CCCCCCCCCCCCS(O)(=O)=O LDMOEFOXLIZJOW-UHFFFAOYSA-N 0.000 description 1
- RVHOBHMAPRVOLO-UHFFFAOYSA-N 2-ethylbutanedioic acid Chemical compound CCC(C(O)=O)CC(O)=O RVHOBHMAPRVOLO-UHFFFAOYSA-N 0.000 description 1
- YHVUVJYEERGYNU-UHFFFAOYSA-N 4',8-Di-Me ether-5,7,8-Trihydroxy-3-(4-hydroxybenzyl)-4-chromanone Natural products COC1(C)CC(O)OC(C)C1O YHVUVJYEERGYNU-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 208000007814 Unstable Angina Diseases 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000012754 cardiac puncture Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- AJSDVNKVGFVAQU-BIIVOSGPSA-N cladinose Chemical compound O=CC[C@@](C)(OC)[C@@H](O)[C@H](C)O AJSDVNKVGFVAQU-BIIVOSGPSA-N 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 125000001072 heteroaryl group Chemical group 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000011533 pre-incubation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- DDMGAAYEUNWXSI-XVSDJDOKSA-M sodium;(5z,8z,11z,14z)-icosa-5,8,11,14-tetraenoate Chemical compound [Na+].CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC([O-])=O DDMGAAYEUNWXSI-XVSDJDOKSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 235000019871 vegetable fat Nutrition 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9714358 | 1997-11-17 | ||
| FR9714358A FR2771008B1 (fr) | 1997-11-17 | 1997-11-17 | Utilisation des ketolides pour la preparation de compositions pharmaceutiques destinees a prevenir les complications thrombotiques arterielles liees a l'atherosclerose |
| PCT/FR1998/002436 WO1999025365A1 (fr) | 1997-11-17 | 1998-11-16 | Utilisation des ketolides pour prevenir les complications thrombotiques arterielles liees a l'atherosclerose |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE69825308D1 DE69825308D1 (de) | 2004-09-02 |
| DE69825308T2 true DE69825308T2 (de) | 2005-08-04 |
Family
ID=9513423
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE69825308T Expired - Lifetime DE69825308T2 (de) | 1997-11-17 | 1998-11-16 | Verwendung von ketoliden zur vorbeugung von mit atherosklerose zusammenhängender thrombotischer komplikationen |
Country Status (35)
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2777282B1 (fr) * | 1998-04-08 | 2001-04-20 | Hoechst Marion Roussel Inc | Nouveaux derives de la 2-fluoro 3-de((2,6-dideoxy 3-c-methyl 3-0-methyl-alpha-l-ribohexopyranosyl) oxyl) 6-o-methyl 3-oxo erythromycine, leur procede de preparation et leur application a la synthese de principes actifs de medicaments |
| WO2000034297A1 (en) | 1998-12-10 | 2000-06-15 | Pfizer Products Inc. | Carbamate and carbazate ketolide antibiotics |
| AU1675400A (en) * | 1999-01-27 | 2000-08-18 | Pfizer Products Inc. | Ketolide antibiotics |
| EP1114826A3 (en) * | 1999-12-29 | 2001-10-31 | Pfizer Products Inc. | Novel antibacterial and prokinetic macrolides |
| ATE437860T1 (de) | 2000-04-04 | 2009-08-15 | Smithkline Beecham Plc | 2-hydroxy-mutilin-carbamat derivate und ihre anwendung als antibakterielle mittel |
| JP2004323414A (ja) * | 2003-04-24 | 2004-11-18 | Japan Science & Technology Agency | １４員環マクロライド化合物を利用した、血管平滑筋の増殖に起因する疾患治療剤 |
| GB0402578D0 (en) * | 2004-02-05 | 2004-03-10 | Cambridge Theranostics Ltd | Methods of treatment of atherosclerosis |
| EP2613630A4 (en) * | 2010-09-10 | 2014-01-15 | Cempra Pharmaceuticals Inc | HYDROGEN BOND FOR THE PREPARATION OF FLUOROCHETOLIDES FOR THE TREATMENT OF DISEASES |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1992022819A1 (en) * | 1991-06-14 | 1992-12-23 | Board Of Regents Of The University Of Washington | Diagnosis and treatment of arterial chlamydial granuloma |
| FR2718450B1 (fr) * | 1994-04-08 | 1997-01-10 | Roussel Uclaf | Nouveaux dérivés de l'érythromycine, leur procédé de préparation et leur application comme médicaments. |
| FR2719587B1 (fr) * | 1994-05-03 | 1996-07-12 | Roussel Uclaf | Nouveaux dérivés de l'érythromycine, leur procédé de préparation et leur application comme médicaments. |
| FR2742757B1 (fr) * | 1995-12-22 | 1998-01-30 | Roussel Uclaf | Nouveaux derives de l'erythromycine, leur procede de preparation et leur application comme medicaments |
| US6271255B1 (en) * | 1996-07-05 | 2001-08-07 | Biotica Technology Limited | Erythromycins and process for their preparation |
| GB9621771D0 (en) * | 1996-10-18 | 1996-12-11 | St George S Enterprises Ltd | Method of treatment of heart disease |
| FR2757168B1 (fr) * | 1996-12-12 | 1999-06-11 | Hoechst Marion Roussel Inc | Nouveaux derives de l'erythromycine, leur procede de preparation et leur application comme medicaments |
| EP0895999A1 (en) * | 1997-08-06 | 1999-02-10 | Pfizer Products Inc. | C-4" substituted macrolide antibiotics |
-
1997
- 1997-11-17 FR FR9714358A patent/FR2771008B1/fr not_active Expired - Fee Related
-
1998
- 1998-11-12 ZA ZA9810357A patent/ZA9810357B/xx unknown
- 1998-11-13 TW TW087118866A patent/TW472061B/zh not_active IP Right Cessation
- 1998-11-16 NZ NZ504305A patent/NZ504305A/xx unknown
- 1998-11-16 AP APAP/P/2000/001825A patent/AP1196A/en active
- 1998-11-16 EP EP98955662A patent/EP1030673B1/fr not_active Expired - Lifetime
- 1998-11-16 WO PCT/FR1998/002436 patent/WO1999025365A1/fr not_active Ceased
- 1998-11-16 EA EA200000531A patent/EA003322B1/ru not_active IP Right Cessation
- 1998-11-16 EE EEP200000244A patent/EE04095B1/xx not_active IP Right Cessation
- 1998-11-16 IL IL13614998A patent/IL136149A0/xx unknown
- 1998-11-16 CN CN98813159A patent/CN1286633A/zh active Pending
- 1998-11-16 AU AU12425/99A patent/AU744419B2/en not_active Ceased
- 1998-11-16 DZ DZ980264A patent/DZ2654A1/xx active
- 1998-11-16 AT AT98955662T patent/ATE271875T1/de not_active IP Right Cessation
- 1998-11-16 ID IDW20000930A patent/ID24940A/id unknown
- 1998-11-16 MA MA25348A patent/MA26566A1/fr unknown
- 1998-11-16 SK SK704-2000A patent/SK7042000A3/sk unknown
- 1998-11-16 HR HR20000314A patent/HRP20000314A2/hr not_active Application Discontinuation
- 1998-11-16 PL PL98340373A patent/PL340373A1/xx unknown
- 1998-11-16 TR TR2000/01384T patent/TR200001384T2/xx unknown
- 1998-11-16 TN TNTNSN98206A patent/TNSN98206A1/fr unknown
- 1998-11-16 JP JP2000520798A patent/JP4550273B2/ja not_active Expired - Fee Related
- 1998-11-16 ES ES98955662T patent/ES2224446T3/es not_active Expired - Lifetime
- 1998-11-16 KR KR1020007005317A patent/KR20010032130A/ko not_active Ceased
- 1998-11-16 BR BR9814199-6A patent/BR9814199A/pt not_active Application Discontinuation
- 1998-11-16 CA CA002312021A patent/CA2312021C/fr not_active Expired - Fee Related
- 1998-11-16 DE DE69825308T patent/DE69825308T2/de not_active Expired - Lifetime
- 1998-11-16 GE GEAP19985410A patent/GEP20032968B/en unknown
- 1998-11-16 HU HU0004507A patent/HUP0004507A3/hu unknown
- 1998-11-16 YU YU29600A patent/YU29600A/sh unknown
- 1998-11-17 AR ARP980105823A patent/AR014119A1/es not_active Application Discontinuation
-
2000
- 2000-05-11 BG BG104427A patent/BG104427A/xx unknown
- 2000-05-11 NO NO20002435A patent/NO20002435L/no unknown
- 2000-05-17 OA OA1200000144A patent/OA11411A/fr unknown
-
2007
- 2007-09-28 US US11/863,329 patent/US20080139489A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE2815578C2 (de) | Neue pharmazeutische Verwendung von Nimodipin | |
| DE69005992T2 (de) | Psychotropische Wirkstoffe enthaltende stabilisierte Lösungen. | |
| DE69732049T2 (de) | Pharmazeutische zubereitungen, enthaltend salze von hyaluronsäure und lokalanästhetika | |
| DE69612465T2 (de) | Verwendung von Rifamyciderivaten zur Behandlung von Chlamydia-Infektionen | |
| DE69728783T2 (de) | Verbesserte arzneimittel | |
| DE69429299T2 (de) | Verwendung von Tachykinin-Antagonisten zur Behandlung von Erbrechen | |
| DE69902526T2 (de) | Verbesserung der antibakteriellen wirkung von oxazolidinon durch arginin derivate | |
| DE19720312A1 (de) | Zubereitung mit erhöhter in vivo Verträglichkeit | |
| DE69930271T2 (de) | Medizinische zusammensetzungen zur behandlung von augenerkrankungen | |
| DE69825308T2 (de) | Verwendung von ketoliden zur vorbeugung von mit atherosklerose zusammenhängender thrombotischer komplikationen | |
| DE2634903C2 (de) | Tetrahydrothieno-[3,2-c]-pyridin-Derivate und sie enthaltende Arzneimittel | |
| DE69819900T2 (de) | Wässrige flüssige pharmazeutische zusammensetzung enthaltend ein benzopyranderivat als hauptbestandteil | |
| DE2740281A1 (de) | Verwendung von 4-carbamoyl-5-hydroxyimidazol bei der behandlung von krebs, rheumatismus und nephritis | |
| DE69004921T2 (de) | Injizierbare Cephalosporinpräparate und ihre Anwendung. | |
| DE2951671C2 (de) | Arzneimittelzubereitung mit Antithrombosewirkung und Hemmwirkung auf die Agglomeration der Blutplättchen | |
| DE69115528T2 (de) | Neue pharmazeutische Verwendungen von Forskolin-Derivaten | |
| DE2557431A1 (de) | Topische antimikrobielle praeparate | |
| DE69003670T2 (de) | Nicht einspritzbares karzinostatisches mittel zur vorbeugung der entzündung durch 5-fluoruracil und verfahren zur behandlung von krebs. | |
| DE60302951T2 (de) | Organisches Säuresalz von Amlodipine | |
| DE69117879T2 (de) | Arzneimittel für die Verhütung und Behandlung von Krankheiten der Kreislauforgane enthaltend Spiro-3-heteroazolidin-Verbindungen | |
| DE69232409T2 (de) | Ungepufferte, vorgemischte ranitidin-formulierung | |
| DE68912740T2 (de) | Azazyklische Derivate mit harntreibender Wirkung. | |
| DE60300683T2 (de) | Prucaloprid-n-oxid | |
| DE69919789T2 (de) | Loratadin zur Verwendung als Antiarrhythmikum | |
| DD270656A5 (de) | Verfahren zur herstellung eines aeusserlich anwendbaren, antiviralen, in der haut akkumulierenden pharmazeutischen praeparates |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition | ||
| 8328 | Change in the person/name/address of the agent |
Representative=s name: PFENNING MEINIG & PARTNER GBR, 80339 MUENCHEN |
|
| 8328 | Change in the person/name/address of the agent |
Representative=s name: MAIWALD PATENTANWALTSGESELLSCHAFT MBH, 80335 MUENC |